I-Mab Enters into Strategic Regional Partnership with Kalbe Genexine Biologics for Commercialization Rights of CD73 Antibody, TJD5, for Immuno-Oncology

NEXT STORY
PhaseBio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Recent Business Highlights
PREV STORY
Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Bavarian Nordic Announces Acceptance of Abstracts and Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

COPENHAGEN, Denmark, May 16, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today ...

author_avatar
NASDAQ Market News

FDA approves Roche’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older

author_avatar
NASDAQ Market News

Madrigal Pharmaceuticals Reports 2020 First Quarter Financial Results and Highlights

author_avatar
NASDAQ Market News